Director/PDMR Shareholding

Dechra Pharmaceuticals PLC

15 January 2024

 

15 January 2024

Dechra^® Pharmaceuticals PLC

(Dechra or the Company)

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

Dechra Pharmaceuticals PLC announces that following the Court sanctioning the Scheme at the Sanction Hearing on 12 January 2024, the following PDMRs acquired ordinary shares of 1p each in the Company pursuant to awards granted to them under the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP), the Deferred Bonus Plan 2021 and the Global Save As You Earn Plan 2018 (SAYE) as detailed in the tables below. All shares were subject to the Cash Offer of the Company at £38.75 per share:

Long Term Incentive Plan, SAYE and Deferred Bonus Plan

Name	Capacity	Date of Grant	Award	Cost	Shares Acquired & Sold
Ian Page	Director	22 September 2020*	Qualifying LTIP*	Nil	5,372
Ian Page	Director	22 September 2020*	Qualifying CSOPŦ	£32.37	155
Ian Page	Director	16 September 2021	LTIP**	Nil	18,551
Ian Page	Director	9 September 2022	LTIP **	Nil	20,193
Ian Page	Director	20 September 2022	Deferred Bonus Plan	Nil	3,580
Ian Page	Director	19 October 2020	SAYE	£28.68	627
Paul Sandland	Director	22 September 2020*	LTIP*	Nil	2,335
Paul Sandland	Director	16 September 2021	LTIP**	Nil	8,600
Paul Sandland	Director	9 September 2022	Qualifying LTIP**	Nil	9,983
Paul Sandland	Director	9 September 2022	Qualifying CSOP ±	£31.99	227
Paul Sandland	Director	20 September 2022	Deferred Bonus Plan	Nil	2,293
Paul Sandland	Director	19 October 2020	SAYE	£28.68	627

*The vesting of the awards was subject to the achievement of performance conditions which were satisfied to the extent that the awards vested at 16.4%.

Ŧ Ian Page exercised the linked tax qualifying option at an exercise price of £32.37 as part of his LTIP award. 25 nil cost options were forfeited to the value of that gain.

 ** Both the EPS and ROCE performance conditions for LTIP awards granted in 2021 and 2022 were deemed to have been met as detailed in the Co-Operation Agreement between the Company and Freya Bidco Limited. The TSR performance conditions was measured for both awards. The awards taking into account all of the performance conditions vested at 90.8% for the 2021 grant and 100% for the 2022 grant. Both awards were pro rata for time.

± Paul Sandland exercised the linked tax qualifying option at an exercise price of £31.99 as part of his LTIP award. 39 nil cost options were forfeited to the value of that gain.

Deferred Bonus Plan 2021 (Cash Settled)

Ian Page and Paul Sandland were granted on 18 October 2023, 1,080 and 715 awards respectively under the Deferred Bonus Plan 2021. These were cash settled in accordance with the Co-Operation Agreement between the Company and Freya Bidco Limited.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

Notification of Dealing Forms

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 5,372
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £32.37	Volume(s) 155
d)	Aggregated information -    Aggregate volume -    Price -    Total	155 £32.37 £5,017.35
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 18,551
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 20,193
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Deferred Bonus Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 3,580
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Global Save As You Earn Plan
c)	Price(s) and volumes(s)	Price(s) £28.68	Volume(s) 627
d)	Aggregated information -    Aggregate volume -    Price -    Total	627 £28.68 £17,982.36
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 2,335
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 8,600
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 9,983
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) £31.99	Volume(s) 227
d)	Aggregated information -    Aggregate volume -    Price -    Total	227 £31.99 £7,261.73
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Deferred Bonus Plan
c)	Price(s) and volumes(s)	Price(s) £Nil Cost	Volume(s) 2,293
d)	Aggregated information -    Aggregate volume -    Price -    Total	N/A
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Paul Sandland
2.	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Acquisition of shares pursuant to the Company's Global Save As You Earn Plan
c)	Price(s) and volumes(s)	Price(s) £28.68	Volume(s) 627
d)	Aggregated information -    Aggregate volume -    Price -    Total	627 £28.68 £17,982.36
e)	Date of the transaction	2024.01.15
f)	Place of the transaction	Outside a trading venue

For further information, please contact:

Melanie Hall, Company Secretary                          

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END